The important role of NFAT1-MDM2 pathway in InuA's anticancer activity has also been validated in both NFAT1 KD and MDM2 KD breast cancer cell lines (both p53 wild-type and mutant). This evidence concerns the gene NFATC2 and breast carcinoma.